Novaferon is under clinical development by Genova Biotech and currently in Phase III for Coronavirus Disease 2019 (COVID-19). According to GlobalData, Phase III drugs for Coronavirus Disease 2019 (COVID-19) have a 13% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Novaferon’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Novaferon overview
Novaferon is a interferon act as immunostimulant agent. It is formulated as injectable solution for intramuscular route of administration. Novaferon is indicated for the treatment of HBeAg-positive chronic hepatitis B, patients with advanced cancer: used to extend survival and improve quality of life, in combination with chemotherapy: the treatment of patients with common malignancies, after tumor surgery or for cancer chemotherapy patients: to prevent cancer recurrence and metastasis, thereby improving the cure rate and survival rate of cancer patients, for cancer prevention: novaferon due to adverse events was a transient, and therefore expected to relatively healthy, negative imaging, but the tumor-associated individual crowd abnormalities in regular use of low doses to reduce the cancer marker levels, to prevent and reduce the incidence of malignant tumors, viral infections, such as Hepatitis C, avian influenza, HIV (AIDS) and genital wart, rheumatoid arthritis, multiple sclerosis, systemic lupus erythematosus and other autoimmune diseases.
Novaferon is under development for the treatment of Coronavirus disease 2019 (COVID-19). The drug candidate is administered through intramuscular. It was also under development for metastatic neuroendocrine tumors, metastatic colorectal cancer, pancreatic cancer, melanoma, liver cancer, gastric cancer, non-small cell lung cancer, rheumatoid arthritis and breast cancer.
For a complete picture of Novaferon’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
